Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
As US Court Chops Another Symbicort Patent, Will Viatris Make Its Move?
AstraZeneca Tells Generics Bulletin It May Appeal Invalidity Ruling
Nov 11 2022
•
By
Dean Rudge
Viatris is looking to break AZ's 16 year monopoly • Source: Shutterstock
More from Legal & IP
More from Generics Bulletin